Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Yukihiro, Yano"'
Autor:
Moto Yaga, Kana Hasegawa, Shunya Ikeda, Miwa Matsubara, Takashi Hiroshima, Toru Kimura, Yuya Shirai, Wibowo Tansri, Hirofumi Uehara, Mana Tachikawa, Yuzuru Okairi, Masayuki Sone, Hiromi Mori, Yosuke Kogue, Hiroki Akamine, Daisuke Okuzaki, Kotaro Kawagishi, Satoshi Kawanaka, Hiroyuki Yamato, Yukiyasu Takeuchi, Eiji Okura, Ryu Kanzaki, Jiro Okami, Itsuko Nakamichi, Shigeru Nakane, Aki Kobayashi, Takashi Iwazawa, Toshiteru Tokunaga, Hideoki Yokouchi, Yukihiro Yano, Junji Uchida, Masahide Mori, Kiyoshi Komuta, Tetsuro Tachi, Hideki Kuroda, Noriyuki Kijima, Haruhiko Kishima, Michiko Ichii, Shinji Futami, Yujiro Naito, Takayuki Shiroyama, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Yoshito Takeda, Soichiro Funaki, Yasushi Shintani, Atsushi Kumanogoh, Naoki Hosen
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Chimeric antigen receptor (CAR) T cells are effective against hematological cancers, but are less effective against solid tumors such as non-small cell lung cancer (NSCLC). One of the reasons is that only a few cell surface targets specific
Externí odkaz:
https://doaj.org/article/dba8be21cd884b8998cbf922a845b421
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract This pilot study analyzed the dietary patterns of patients with non-small cell lung cancer undergoing initial pembrolizumab, an immune checkpoint inhibitor (ICI), treatment in the month before treatment. Serum fatty acid fractions and their
Externí odkaz:
https://doaj.org/article/ef483d21521247408ffc61a446c551fe
Autor:
Kota Iwahori, Takeshi Uenami, Yukihiro Yano, Toshihiko Ueda, Mari Tone, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Takayuki Shiroyama, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hiroshi Kida, Masahide Mori, Yoshito Takeda, Atsushi Kumanogoh, Hisashi Wada
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Anti-programmed cell death-1 (PD-1) therapy exerts beneficial effects in a limited population of cancer patients. Therefore, more accurate diagnostics to predict the efficacy of anti-PD-1 therapy are desired. The present study investigated w
Externí odkaz:
https://doaj.org/article/8013754f2723460595a34a91b32d649c
Autor:
Yuki Akazawa, Aki Yoshikawa, Masaki Kanazu, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Publikováno v:
Thoracic Cancer, Vol 13, Iss 17, Pp 2450-2458 (2022)
Abstract Background Since 2015, immune checkpoint inhibitors have been a clinical treatment strategy for patients with advanced or recurrent non‐small cell lung cancer (NSCLC). However, the relationship between immune‐related adverse event (irAE)
Externí odkaz:
https://doaj.org/article/213e6379857b4fbea92817af79621d96
Autor:
Tomoki Kuge, Fukuko Okabe, Yuji Yamamoto, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Publikováno v:
Thoracic Cancer, Vol 12, Iss 12, Pp 1935-1939 (2021)
Abstract Pulmonary pleomorphic carcinoma is a rare malignant tumor that grows rapidly and has a poor prognosis. Although no effective treatments have so far been established, immune checkpoint inhibitors (ICIs) have shown clinical improvement in some
Externí odkaz:
https://doaj.org/article/3d7c898c611448c8a4bfc7e1200eed9c
Autor:
Reina Hara, Masaki Kanazu, Ami Iwai, Tomoki Kuge, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Publikováno v:
Thoracic Cancer, Vol 12, Iss 9, Pp 1441-1444 (2021)
Abstract Here, we report a rare case involving a 66‐year‐old man with epidermal growth factor receptor (EGFR)‐mutant lung adenocarcinoma and antisynthetase syndrome (ASS) treated with osimertinib. The patient presented with respiratory failure
Externí odkaz:
https://doaj.org/article/9c12300c55c6493eac2515df83e5dfc4
Autor:
Yuji Yamamoto, Yukihiro Yano, Tomoki Kuge, Fukuko Okabe, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3317-3325 (2020)
Background Pirfenidone is an antifibrotic agent that is potentially effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, no study has reported on its prophylactic value against chemotherapy‐associated acute IPF exacerbations
Externí odkaz:
https://doaj.org/article/a5581418ca0541438c37363c641a7c11
Publikováno v:
Respirology Case Reports, Vol 9, Iss 9, Pp n/a-n/a (2021)
Abstract Obstructive endobronchial tumours often cause decreased quality of life. Bronchial ethanol injection (BEI) therapy is considered an effective modality for airway dilatation or haemoptysis without specialist equipment. Here, we report experie
Externí odkaz:
https://doaj.org/article/c5e389f838884dc498e3e9715472700e
Autor:
Akio Osa, Takeshi Uenami, Yujiro Naito, Haruhiko Hirata, Shohei Koyama, Takayuki Takimoto, Takayuki Shiroyama, Shinji Futami, Saeko Nakatsubo, Nobuhiko Sawa, Yukihiro Yano, Izumi Nagatomo, Yoshito Takeda, Masahide Mori, Hiroshi Kida, Atsushi Kumanogoh
Publikováno v:
Thoracic Cancer, Vol 10, Iss 11, Pp 2183-2187 (2019)
Recent clinical trials have demonstrated that anti‐PD‐1 blocking antibodies showed remarkable clinical efficacy in a subset of non‐small cell lung cancer (NSCLC) patients. Clinical trials usually exclude patients with renal dysfunction who are
Externí odkaz:
https://doaj.org/article/addd5ae67c1742ff8f10f548266ee3b5
Publikováno v:
Respirology Case Reports, Vol 8, Iss 7, Pp n/a-n/a (2020)
Abstract Asbestos‐related pulmonary conditions such as benign asbestos pleural effusion (BAPE) and diffuse pleural thickening (DPT) can develop after many years of asbestos exposure. These conditions cause progressing constrictive deficit in pulmon
Externí odkaz:
https://doaj.org/article/281328692d3946edb9ca7706bc0cedd2